CMPX - Compass Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CMPX is currently covered by 5 analysts with an average price target of $12.31. This is a potential upside of $9.59 (352.57%) from yesterday's end of day stock price of $2.72.

Compass Therapeutics's activity chart (see below) currently has 9 price targets and 24 ratings on display. The stock rating distribution of CMPX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 11.11% with an average time for these price targets to be met of 40.11 days.

Highest price target for CMPX is $32, Lowest price target is $5, average price target is $17.

Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 12-Aug-2025. First documented stock forecast 01-Oct-2021.

Currently out of the existing stock ratings of CMPX, 16 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$32

$29.03 (977.44%)

$32

7 days ago
(12-Aug-2025)

0/6 (0%)

$28.83 (909.46%)

Buy

$24

$21.03 (708.08%)

$24

3 months 29 days ago
(21-Apr-2025)

0/6 (0%)

$22.22 (1248.31%)

Buy

$5

$2.03 (68.35%)

$7

11 months 3 days ago
(16-Sep-2024)

0/3 (0%)

$3.29 (192.40%)

Buy

$8

1 years 12 days ago
(07-Aug-2024)

0/1 (0%)

$4.82 (151.57%)

Buy

$7

$4.03 (135.69%)

$8

1 years 3 months 6 days ago
(13-May-2024)

0/2 (0%)

$5.44 (348.72%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CMPX (Compass Therapeutics) average time for price targets to be met?

On average it took 40.11 days on average for the stock forecasts to be realized with a an average price target met ratio 11.11

Which analyst has the current highest performing score on CMPX (Compass Therapeutics) with a proven track record?

DANE LEONE

Which analyst has the current lower performing score on CMPX (Compass Therapeutics) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on CMPX (Compass Therapeutics)?

Dane Leone works at RAYMOND JAMES and has 4 price targets and 5 ratings on CMPX

Which analyst is the currently most bullish on CMPX (Compass Therapeutics)?

Jason Kolbert with highest potential upside - $29.03

Which analyst is the currently most reserved on CMPX (Compass Therapeutics)?

Andrew Berens with lowest potential downside - -$0

Compass Therapeutics in the News

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?